NGL Fine-Chem Limited announced that Mr. Rahul Nachane, Managing Director of the Company, will have a meeting with Investor(s)/Analyst(s) on Friday, 20th June 2025.
The meeting will be a one-on-one physical meeting.
The investor presentation has been submitted to the stock exchange and uploaded on the company's website.
NGL Fine-Chem Limited held an investor conference call on May 26, 2025, regarding the unaudited financial results for Q4 and the year ended March 31, 2025.
Revenue from operations for Q4 FY25 stood at ₹94.97 crores, a 6.6% sequential increase but a 4.8% year-on-year decline. Full-year FY25 revenue was ₹368.26 crores, an 8.7% increase over FY24.
EBITDA for Q4 FY25 was ₹6.32 crores, up 24% sequentially but down 60% year-on-year. The EBITDA margin for the quarter was 6.7%, an improvement of 93 basis points over Q3 FY25 but down 921 basis points year-on-year. Full-year EBITDA was ₹33.87 crores with a margin of 9.2%.
Profit after tax for Q4 FY25 stood at ₹0.54 crores compared to ₹1.28 crores in Q3 FY25 and ₹12.33 crores in Q4 FY24. Full-year profit after tax was ₹21.12 crores, down 49% from ₹41.32 crores in FY24.
The company successfully commercialized Phase 1 of its capex project, including clean room and associated utilities, with validation batches underway.
Phase 2 of the capex project is expected to be completed by Q3 of the current financial year, with a total outlay estimated at approximately ₹160 crores, financed through a 60-40 debt-equity structure. Meaningful contributions are expected from the end of FY27 onwards.
Management Commentary: Rahul Nachane, Managing Director, noted that the operating environment in Q4 FY25 remained challenging due to heightened competition and subdued realizations. He also mentioned geopolitical tensions and currency availability issues impacting business in certain regions. The company is focused on operational excellence and prudent capital allocation. They anticipate margin improvement in the next 3-6 months through process re-engineering.
The company has received CEP certificates for 3 APIs and DMF filings for 5 products. Some sales have already started from these approvals, with plans to build on this and target more customer acquisition. They expect to generate ₹25 crores to ₹30 crores in the current year from EU sales.
The company hopes to file for U.S. FDA approval by the end of the calendar year, with approval expected in 2027. They have onboarded 5 customers in the EU and sales have already started. The total scale of the 3 products which they have got is probably to the tune of about INR30 crores, INR35 crores, when we look at the European and U.S. market.
NGL Fine-Chem is primarily focused on veterinary APIs, with 95% of its business in this segment. They are also developing products for the companion animal health segment.
The company anticipates margin expansion of at least 10-15% from regulated markets once they scale up.
NGL Fine-Chem Limited's Board met on 22 May 2025 and approved the audited financial results (standalone and consolidated) for the quarter and year ended 31 March 2025.
Recommended a final dividend of ₹1.75 per equity share of ₹5 each for the financial year ended 31 March 2025.
The 44th Annual General Meeting (AGM) will be held on 19 August 2025 via video conferencing.
The record date for the AGM and payment of final dividend is 12 August 2025; dividend payout will be on or after 26 August 2025.
The Register of Members and Share transfer books will be closed from 12 August 2025 to 19 August 2025 (both days inclusive).
Mr. Hemant Shetye of HSPN & Associates LLP appointed as Scrutinizer for the AGM.
HSPN & Associates LLP appointed as Secretarial Auditors for 5 consecutive financial years from 2025-2026 to 2029-2030.
KD Practice Consulting Pvt. Ltd. appointed as Internal Auditors for the financial year 2025-26.
Sanghavi Randeria & Associates appointed as Cost Auditor for the financial year 2025-2026.
Mr. Sudhir Deo (DIN: 01122338) appointed as an Additional Director (Non-Executive Independent Director) for a first term of 5 consecutive years starting 22 May 2025, subject to shareholder approval.
Mr. Rahul Nachane (DIN: 00223346) appointed as Managing Director of the Company from 1 June 2025, subject to shareholder approval.
Consolidated revenue from operations for the year ended March 31, 2025 stood at ₹36,625.67 lakhs compared to ₹33,868.84 lakhs in the previous year.
Standalone revenue from operations for the year ended March 31, 2025 was ₹35,929.35 lakhs compared to ₹32,897.28 lakhs in the previous year.
The board has recommended a dividend of ₹1.75 per share aggregating to ₹108.12 lakhs
NGL Fine-Chem Limited announced its investor presentation for the quarter and year ended March 31, 2025.
The operating environment in Q4 FY25 remained challenging due to subdued demand and increased competition.
Geopolitical tensions between India and Pakistan impacted business in that region.
Phase 1 of the CAPEX project, including a clean room, has been commercialized, with validation batches underway.
Phase 2 of the CAPEX is expected to be completed by Q3 of the current financial year, with a total outlay estimated at approximately ₹160 crore, financed through a 60:40 debt-equity structure; meaningful contributions are expected from FY27 onwards.
Diversification into regulated markets remains a strategic priority.
Segmental Revenue Mix (FY25):
Animal API: 83%
Human API: 5%
Intermediates: 7%
Formulations: 5%
Geographic Mix (FY25):
Asia: 34%
Europe: 30%
India: 22%
ROW: 12%
USA: 2%
Customer Concentration (FY25):
Top 3 Customers: 17%
Top 5 Customers: 24%
Top 10 Customers: 35%
Summary of Profit and Loss Statement (₹ in Crores):
Revenue from Operations: ₹368.68 crore (FY25) vs ₹338.26 crore (YoY 8.73%)
Total Income: ₹352.81 crore
EBITDA: ₹33.87 crore
Profit After Tax: ₹21.12 crore
Management Commentary: The operating environment in Q4 FY25 remained challenging. Uncertainty persists regarding the duration of this downcycle. Despite these headwinds, we are pleased to report the successful commercialisation of Phase 1 of our CAPEX project during the quarter.